HomeCompareHBMHF vs SBUX

HBMHF vs SBUX: Dividend Comparison 2026

HBMHF yields 128.21% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBMHF wins by $11.44M in total portfolio value
10 years
HBMHF
HBMHF
● Live price
128.21%
Share price
$1.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.60M
Annual income
$4,575,129.27
Full HBMHF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — HBMHF vs SBUX

📍 HBMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBMHFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBMHF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBMHF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBMHF
Annual income on $10K today (after 15% tax)
$10,897.44/yr
After 10yr DRIP, annual income (after tax)
$3,888,859.88/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, HBMHF beats the other by $3,832,895.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBMHF + SBUX for your $10,000?

HBMHF: 50%SBUX: 50%
100% SBUX50/50100% HBMHF
Portfolio after 10yr
$5.88M
Annual income
$2,320,484.69/yr
Blended yield
39.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

HBMHF
No analyst data
Altman Z
8.0
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBMHF buys
0
SBUX buys
0
No recent congressional trades found for HBMHF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBMHFSBUX
Forward yield128.21%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$11.60M$157.5K
Annual income after 10y$4,575,129.27$65,840.13
Total dividends collected$10.60M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: HBMHF vs SBUX ($10,000, DRIP)

YearHBMHF PortfolioHBMHF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$23,521$12,820.51$11,107$407.21+$12.4KHBMHF
2$53,349$28,181.78$12,512$626.87+$40.8KHBMHF
3$116,823$59,739.54$14,366$978.69+$102.5KHBMHF
4$247,259$122,259.11$16,929$1,557.50+$230.3KHBMHF
5$506,405$241,837.18$20,658$2,543.80+$485.7KHBMHF
6$1,004,750$462,896.88$26,406$4,302.22+$978.3KHBMHF
7$1,933,425$858,342.70$35,877$7,622.00+$1.90MHBMHF
8$3,612,406$1,543,641.03$52,741$14,352.64+$3.56MHBMHF
9$6,560,727$2,695,452.74$85,676$29,243.03+$6.48MHBMHF
10$11,595,107$4,575,129.27$157,513$65,840.13+$11.44MHBMHF

HBMHF vs SBUX: Complete Analysis 2026

HBMHFStock

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Full HBMHF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this HBMHF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBMHF vs SCHDHBMHF vs JEPIHBMHF vs OHBMHF vs KOHBMHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.